Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of ibrutinib + R-GemOx-Dexa followed by ibrutinib maintenance in relapsed/refractory non-GCB diffuse large B-cell lymphoma
2015-005390-21Phase 2Completed
- Sponsor
- GELTAMO
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in diffuse large B-cell lymphoma (DLBCL), sponsored by GELTAMO. Primary endpoint: Overall response rate. Started Jan 2016; status: completed.
02
Drugs
ibrutinib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on 2015-005390-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-005390-21.